Last Updated : January 7, 2025
Details
FilesGeneric Name:
nivolumab
Project Status:
Active
Therapeutic Area:
Hodgkin lymphoma
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0376-000
Call for patient/clinician input closed:
NOC Status at Filing:
N/A
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
With doxorubicin, vinblastine and dacarbazine (AVD) in previously untreated stage III or IV Hodgkin Lymphoma.
| Submission received | November 27, 2024 |
|---|---|
| Expert committee meeting (initial) | May 15, 2025 |
Files
Last Updated : January 7, 2025